Physician-initiated Medication Review in a Type 2 Diabetes Outpatient Clinic

Polypharmacy Clinical Trial

Official title:

Physician-initiated Medication Review in a Type 2 Diabetes Outpatient Clinic

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05501223
• Other study ID #: P-2020-1012
• Status: Recruiting
• Phase: N/A
• Start date: November 1, 2020
• Est. completion date: November 2022

Study information

• Verified date: August 2022
• Source: Bispebjerg Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Aiming to reduce polypharmacy in patients with type 2 diabetes by using physician-initiated medication reviews.

Description:

Patients will be randomised to either standard care(annual visit at outpatient clinic) or standard care plus an intervention. The intervention is a medication consultation of 30-60 minutes that consist of a medication review and increased cross-sectoral communication. Follow-up is 6 months. Primary outcome are number of medications used, secondary outcomes are health related quality of life and persistance of medication changes.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 50
• Est. completion date: November 2022
• Est. primary completion date: November 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

1. DM2

2. 12 medications in the central prescription list

Exclusion Criteria:

1. inability to give written consent (e.g., inability to understand the intervention or language barriers);

2. active cancer or palliative treatment;

3. admitted to the hospital.

Related Conditions & MeSH terms

• Polypharmacy

Intervention

Other:
• Medication review
30-60 minutes extra consultation regarding the patients drugs
• Standard care
Standard care i.e. visit at the Dept. of Endocrinology.

Locations

Country	Name	City	State
Denmark	Bispebjerg Hospital	Copenhagen

Sponsors (1)

Lead Sponsor	Collaborator
Bispebjerg Hospital

Country where clinical trial is conducted

Denmark, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of medications used at baseline compared to number of medications used at follow-up. Resulting in a rate of medications used at baseline compared to follow-up i.e. no. medication at follow-up/no. at baseline.	The no. of medications used at baseline will be compared to the no. of medications used at follow-up. This will result in a rate i.e. no. at follow-up/no. at baseline which can be compared between groups resulting in a rate ratio. Medication usage is determined by number of medications listed in the central prescription list.	6 months
Secondary	EQ5D index score. (a Euro Quality of Life 5-dimension 5-level (EQ-5D-5L) scale). The score is retrieved by using the validated EQ5D questionnaire which translates to a corresponding EQ5D index score using country specific value sets.	Health related quality of life measured by EQ5D index score using Danish value sets (ranging from -0.7 (worst quality of life) to 1 (best quality of life)).	6 months